NovaShunt initiates study of its automated fluid removal implant
This article was originally published in Clinica
Executive Summary
Swiss firm NovaShunt has begun a pivotal clinical trial of its implanted automated fluid shunt (AFS) system in the treatment of ascites. Data from the trial will be used in NovaShunt's filing for European approval of the system.
You may also be interested in...
ITF Has A Fight On Its Hands In Duchenne
The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.
AstraZeneca Pays $2bn To Keep Up With The Joneses
Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?